Teleflex Announces the Teleflex Center for Antimicrobial Protection
Teleflex Incorporated (NYSE: TFX) has announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit. Located in Research Triangle, North Carolina, TCAP is dedicated to reducing the spread of infections caused by multidrug-resistant organisms. The center aims to be a resource for patients, physicians, and healthcare organizations through education and partnerships with infection prevention professionals.
TCAP recently sponsored an educational webinar on healthcare-acquired infections, specifically central line-associated bloodstream infections (CLABSI). Teleflex's Arrow™ Brand of Vascular Access Products offers a comprehensive portfolio of antimicrobial Chlorhexidine catheters designed to provide broad-spectrum protection against various pathogens. The company also provides Arrow™ Maximal Barrier Kitting options to protect patients and improve procedural efficiency for clinicians.
Teleflex Incorporated (NYSE: TFX) ha annunciato la creazione del Teleflex Center for Antimicrobial Protection (TCAP), come ramo strategico della sua unità di business Vascular Access. Situato nel Research Triangle, North Carolina, TCAP è dedicato alla riduzione della diffusione di infezioni causate da organismi multiresistenti. Il centro si propone di essere una risorsa per pazienti, medici e organizzazioni sanitarie attraverso l'educazione e partenariati con professionisti della prevenzione delle infezioni.
Recentemente, TCAP ha sponsorizzato un webinar educativo sulle infezioni acquisite in ambito sanitario, specificamente le infezioni del flusso ematico associate a cateteri venosi centrali (CLABSI). Il marchio Arrow™ di Teleflex, dedicato ai prodotti per l'accesso vascolare, offre un portfolio completo di cateteri antimicrobici in Clorexidina progettati per fornire una protezione a largo spettro contro vari patogeni. L'azienda fornisce anche opzioni di Arrow™ Maximal Barrier Kitting per proteggere i pazienti e migliorare l'efficienza procedurale per i clinici.
Teleflex Incorporated (NYSE: TFX) ha anunciado la creación del Teleflex Center for Antimicrobial Protection (TCAP) como una rama estratégica de su unidad de negocio de Acceso Vascular. Ubicado en Research Triangle, Carolina del Norte, TCAP se dedica a reducir la propagación de infecciones causadas por organismos multirresistentes. El centro tiene como objetivo ser un recurso para pacientes, médicos y organizaciones de salud a través de la educación y asociaciones con profesionales de prevención de infecciones.
Recientemente, TCAP patrocinó un seminario web educativo sobre infecciones adquiridas en el entorno sanitario, específicamente infecciones del torrente sanguíneo asociadas a catéteres centrales (CLABSI). La marca Arrow™ de productos de acceso vascular de Teleflex ofrece un portafolio completo de catéteres antimicrobianos de Clorhexidina diseñados para proporcionar protección de amplio espectro contra varios patógenos. La compañía también ofrece opciones de Arrow™ Maximal Barrier Kitting para proteger a los pacientes y mejorar la eficiencia de los procedimientos para los clínicos.
Teleflex Incorporated (NYSE: TFX)는 Vascular Access 사업 부문의 전략적 지점으로 Teleflex Center for Antimicrobial Protection (TCAP)을 설립했다고 발표했습니다. 노스캐롤라이나의 리서치 트라이앵글에 위치한 TCAP는 다제내성 유기체에 의해 발생하는 감염의 확산을 줄이는 데 전념하고 있습니다. 이 센터는 환자, 의사 및 의료 기관을 위한 교육 및 감염 예방 전문가와의 파트너십을 통해 리소스가 되는 것을 목표로 하고 있습니다.
최근 TCAP는 의료 환경에서 획득된 감염, 특히 중심선 관련 혈류 감염(CLABSI)에 관한 교육 웹 세미나를 후원했습니다. Teleflex의 Arrow™ 브랜드 혈관 접근 제품은 다양한 병원체에 대한 폭넓은 보호를 제공하도록 설계된 항균성 클로르헥시딘 카테터의 포괄적인 포트폴리오를 제공합니다. 또한, 이 회사는 Arrow™ Maximal Barrier Kitting 옵션을 제공하여 환자를 보호하고 임상의의 절차 효율성을 개선합니다.
Teleflex Incorporated (NYSE: TFX) a annoncé la création du Teleflex Center for Antimicrobial Protection (TCAP) en tant que branche stratégique de son unité commerciale Vascular Access. Situé à Research Triangle, Caroline du Nord, le TCAP est consacré à la réduction de la propagation des infections causées par des organismes multirésistants. Le centre vise à être une ressource pour les patients, les médecins et les organisations de santé à travers l'éducation et des partenariats avec des professionnels de la prévention des infections.
Récemment, le TCAP a sponsorisé un webinaire éducatif sur les infections acquises dans le domaine de la santé, en particulier les infections du sang associées aux lignes centrales (CLABSI). La marque Arrow™ des produits d'accès vasculaire de Teleflex propose un portefeuille complet de cathéters antimicrobiens en chlorhexidine, conçus pour offrir une protection à large spectre contre divers pathogènes. L'entreprise propose également des options de kit de barrière maximale Arrow™ pour protéger les patients et améliorer l'efficacité procédurale pour les cliniciens.
Teleflex Incorporated (NYSE: TFX) hat die Einrichtung des Teleflex Center for Antimicrobial Protection (TCAP) als strategische Abteilung ihrer Geschäftseinheit Vascular Access angekündigt. Das TCAP, das im Research Triangle, North Carolina, ansässig ist, hat sich der Verringerung der Verbreitung von Infektionen durch multiresistente Organismen verschrieben. Das Zentrum zielt darauf ab, eine Ressource für Patienten, Ärzte und Gesundheitseinrichtungen durch Bildung und Partnerschaften mit Fachleuten zur Infektionsprävention zu sein.
TCAP hat kürzlich ein Bildungswebinar zu im Gesundheitswesen erworbenen Infektionen gesponsert, insbesondere zu zentralvenösen Katheter-assoziierten Blutstrominfektionen (CLABSI). Die Arrow™-Marke von Teleflex für Produkte zum vaskulären Zugang bietet ein umfassendes Portfolio von antimikrobiellen Chlorhexidin-Kathetern, die einen breiten Schutz gegen verschiedene Krankheitserreger bieten. Das Unternehmen bietet auch Arrow™ Maximal Barrier Kitting-Optionen an, um Patienten zu schützen und die Verfahrenseffizienz für die Klinikern zu verbessern.
- Establishment of Teleflex Center for Antimicrobial Protection (TCAP) to focus on reducing infections
- Comprehensive portfolio of antimicrobial Chlorhexidine catheters offering broad-spectrum protection
- Arrow™ Maximal Barrier Kitting options to improve patient protection and clinical efficiency
- None.
Insights
The establishment of the Teleflex Center for Antimicrobial Protection (TCAP) is a significant move in the medical technology sector, especially in the context of combating multidrug-resistant organisms. This initiative aligns with global efforts to reduce healthcare-associated infections (HAIs) and brings Teleflex to the forefront of antimicrobial innovation. The center's focus on education and partnership with professionals in infection prevention demonstrates a proactive approach in addressing a critical healthcare challenge. This could translate to enhanced product credibility and reliability, potentially increasing adoption rates among healthcare facilities.
From a market perspective, TCAP represents a strategic investment that can strengthen Teleflex's position in the vascular access market. The emphasis on antimicrobial catheter technology addresses a pressing need in the healthcare industry, which could drive demand for Teleflex's products. Furthermore, the innovative approach to education and product development might help differentiate Teleflex from competitors. This move could result in increased market share and long-term revenue growth, especially considering the rising concerns over HAIs globally.
Financially, the creation of TCAP could have a positive impact on Teleflex's stock performance. By addressing a significant healthcare problem, the company is likely to see a boost in its brand value and customer trust. This initiative may also lead to new revenue streams through the sale of advanced antimicrobial products. Investors may view this as a forward-thinking strategy that enhances the company's growth potential and market competitiveness. The focus on innovation and education could also attract institutional investors looking for companies with sustainable and impactful business models.
WAYNE, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit led by Chuck Gartner, Director of Marketing - Strategic Initiatives.
The Teleflex Center for Antimicrobial Protection, located in Research Triangle, North Carolina, is dedicated to reducing the spread of infections caused by multidrug-resistant organisms. Too often patients are exposed to these “superbugs” which can lead to additional complications and an increased length of stay in a hospital setting.1 Through education and partnership with professionals in infection prevention, TCAP seeks to be a resource for patients, physicians, and healthcare organizations.
“Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients by helping to reduce vascular access related complications,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular. “We are proud of TCAP’s commitment to antimicrobial catheter technology and our ability to reduce the colonization of major pathogens linked to central line associated blood stream infections (CLABSI).”2
The Teleflex Center for Antimicrobial Protection aims to provide quality products, services, and education to its customers by pioneering catheter protection technology and developing innovative vascular access devices.
TCAP recently sponsored an educational webinar focused on the expansion of surveillance of healthcare-acquired infections (HAI), specifically central line-associated bloodstream infections (CLABSI). That webinar can be viewed on-demand through Teleflex Academy.
Teleflex, through its Arrow™ Brand of Vascular Access Products, has the only comprehensive portfolio of antimicrobial Chlorhexidine catheters designed to provide broad-spectrum protection against gram-positive, gram-negative, and fungal pathogens.2,3,4 Additionally, Arrow™ Maximal Barrier Kitting options provide protection for patients and improve procedural efficiency for clinicians.5 This portfolio of products was showcased at the Association for Professionals in Infection Control and Epidemiology (APIC) 2024 Annual Conference. During the conference, TCAP sponsored an educational Exhibitor Theater session, focused on CLABSI trends. To learn more about Arrow™ Antimicrobial Catheter and Kitting Solutions, visit our website.
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue, Arrowg+ard Blue Advance, Arrowg+ard Blue Plus, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks or registered trademarks of their respective owners. © 2024 Teleflex Incorporated. All rights reserved. MC-009780
References:
- Toor H, Farr S, Savla P, Kashyap S, Wang S, Miulli DE. Prevalence of central line-associated bloodstream infections (CLABSI) in intensive care and medical-surgical units. Cureus. 2022;14(3):e22809.doi:10.7759/cureus.22809
- In vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in vitro/in vivo testing methods and clinical outcomes has currently been ascertained.
- Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of Central Venous Catheter-Related Bloodstream Infection With an 'Antiseptic-Impregnated Catheter: A Randomized, Controlled Trial. Annals of Internal Medicine, August 15, 1997, Vol. 127, Issue 4, pp. 257–266.
- Spangler D and Moss S. In-Vitro Assessment of Antimicrobial Activity of Three Commercially Available Central Venous Catheters. Poster by Arrow (Teleflex) International, Inc. Department of Applied Research. 2010-0406 v1
- Fenik Y, Celebi N, Wagner R, et al. Prepackaged central line kits reduce procedural mistakes during central line insertion: a randomized controlled prospective trial. BMC Medical Education. 2013;13:60. Published 2013 Apr 30. doi:10.1186/1472-6920-13-60. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645964/
Rx only
Contraindications:
The Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ Catheters are contraindicated for patients with known hypersensitivity to chlorhexidine, silver sulfadiazine and/or sulfa drugs.
Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance™ Catheters are contraindicated in the following areas:
• Patients with known hypersensitivity to chlorhexidine
• In presence of device related infections
• In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway.
No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
For complete indications, contraindications, warnings, precautions, and adverse reactions, please refer to each referenced product's full package insert.
Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836
FAQ
What is the purpose of Teleflex's new Center for Antimicrobial Protection (TCAP)?
What products does Teleflex (TFX) offer for antimicrobial protection in vascular access?
Where is the Teleflex Center for Antimicrobial Protection (TCAP) located?
What recent educational initiative has TCAP sponsored related to healthcare-acquired infections?
